Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940052 | 1.00 | PRKCI (0.47) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL17030554 | 0.89 | CTNNB1 (0.42) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL14403556 | 0.89 | CTNNB1 (0.46) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL4060161 | 0.85 | RAB9A (0.45) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL29786197 | 0.85 | RAB9A (0.45) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL3638564 | 0.85 | CHRM2 (0.50) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL10734397 | 0.82 | NPBWR1 (0.41) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL317341 | 0.81 | PRKCI (0.51) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL22549528 | 0.81 | PRKCI (0.47) | PRKCIRAB9APOLBKDM1AMAOA | |
| SCHEMBL4688762 | 0.81 | PRKCI (0.47) | PRKCIRAB9APOLBKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| EP-0794183-B1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 2000-06-14 | — | — | EP | claimed |
| US-5693831-A | (2,3-dihydro-5-benzofuranyl)-acetonitrile | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | claimed |
| EP-0794183-A1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 1997-09-10 | — | — | EP | claimed |
| JP-9241250-A | — | — | None | — | — | JP | disclosed |
| CN-113122061-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7087597-B1 | Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-08 | — | — | US | disclosed |
| EP-1223170-B1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1223170-A1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
| EP-0794183-B1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 2000-06-14 | — | — | EP | disclosed |
| US-5693831-A | (2,3-dihydro-5-benzofuranyl)-acetonitrile | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5693831-A | (2,3-dihydro-5-benzofuranyl)-acetonitrile | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| JP-H09241250-A | (2,3-DIHYDRO-5-BENZOFURANYL)ACETONITRILE | BAYER AG | 1997-09-16 | — | — | JP | disclosed |
| EP-0794183-A1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 1997-09-10 | — | — | EP | disclosed |
| EP-0794183-A1 | (2,3-Dihydro-5-benzofuranyl)-acetonitrile | BAYER AG (DE) | 1997-09-10 | — | — | EP | disclosed |
| US-4177272-A | HYPOTENSIVE, VASODILATION, PARKINSON'S DISEASE | SCIENCE UNION ET CIE (FR) | 1979-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | PRKCI 343/4885RAB9A 3231/4885POLB 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.